GSK to Acquire Oncology Company Nuvalent

GSK plc has entered into an agreement to acquire Nuvalent, a US-based biotechnology company specializing in the development of patient-specific cancer treatments. This acquisition is part of GSK's strategy to bolster its oncology drug pipeline and accelerate the delivery of new therapies to patients.

Nuvalent is recognized for its work on tyrosine kinase inhibitors, which target specific cancer-driving mutations. The acquisition aims to enhance GSK's range of targeted cancer medicines.

Financial terms of the deal have not been disclosed. GSK anticipates that the acquisition of Nuvalent will advance its research and development efforts in oncology, potentially bringing novel and precise treatment options to patients. The company intends to significantly expand its portfolio of oncology products.

This move aligns with GSK's broader objective to streamline operations and concentrate on key growth areas, including cancer therapies. The transaction is anticipated to close in the second half of 2026, subject to customary regulatory approvals and closing conditions.